Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE6D | O43924 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5648873 | 0.86 | PDE6D (0.41) | PDE6DRAB9ANPC1SMN1; SMN2CYP2C19 | |
| SCHEMBL5649617 | 0.84 | GAA (0.42) | PDE6DRAB9ANPC1SMN1; SMN2CYP2C19 | |
| SCHEMBL5651822 | 0.83 | PDE6D (0.39) | PDE6DRAB9ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL5652565 | 0.80 | PDE6D (0.45) | PDE6DRAB9ANPC1SMN1; SMN2CYP2C19 | |
| SCHEMBL5653629 | 0.80 | NPC1 (0.49) | RAB9ANPC1KMT2AHRH3 | |
| SCHEMBL5650413 | 0.76 | ALDH1A1 (0.42) | SMN1; SMN2MEN1KMT2ACYP2C19 | |
| SCHEMBL5652311 | 0.70 | ALDH1A1 (0.38) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL11142733 | 0.68 | TBXAS1 (0.51) | PDE6DRAB9ANPC1KMT2AL3MBTL1 | |
| SCHEMBL5648374 | 0.67 | MAPT (0.41) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL2958974 | 0.67 | PDE6D (0.37) | PDE6DNPC1CYP2C19HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7176215-B2 | Bicyclic oxopyridine and oxopyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2007-02-13 | — | — | US | disclosed |
| US-20040254200-A1 | Bicyclic oxopyridine and oxopyrimidine derivatives | UCB PHARMA S.A. (BE) | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254200-A1 | Bicyclic oxopyridine and oxopyrimidine derivatives | MAPK1, ALK, NAT1 | PDE6D 3483/4885RAB9A 3641/4885PIK3CD 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.